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Abstract: 
Large-scale genome-wide association studies (GWAS) have identified approximately 35 loci 
associated with epithelial ovarian cancer (EOC) risk. The majority of GWAS-identified disease 
susceptibility variants are located in non-coding regions, and causal genes underlying these 
associations remain largely unknown. Here we performed a transcriptome-wide association study 
to search for novel genetic loci and plausible causal genes at known GWAS loci. We used RNA 
sequencing data (68 normal ovarian-tissue samples from 68 individuals and 6,124 cross-tissue 
samples from 369 individuals) and high-density genotyping data from European descendants of 
the Genotype-Tissue Expression (GTEx V6) project to build ovarian and cross-tissue models of 
genetically regulated expression using elastic net methods. We evaluated 17,121 genes for their 
cis-predicted gene expression in relation to EOC risk using summary statistics data from GWAS 
of 97,898 women, including 29,396 EOC cases. With a Bonferroni-corrected significance level 
of P<2.2×10-6, we identified 35 genes including FZD4 at 11q14.2 (Z=5.08, P=3.83×10-7, the 
cross-tissue model; 1 Mb away from any GWAS-identified EOC risk variant), a potential novel 
locus for EOC risk. All other 34 significantly-associated genes were located within 1 Mb of 
known GWAS-identified loci, including 23 genes at 6 loci not previously linked to EOC risk. 
Upon conditioning on nearby known EOC GWAS-identified variants, the associations for 31 
genes disappeared and 3 genes remained (P<1.47 x 10-3). These data identify one novel locus 
(FZD4) and 34 genes at 13 known EOC risk loci associated with EOC risk, providing new 
insights into EOC carcinogenesis. 
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Introduction 
Epithelial ovarian cancer (EOC) has a substantial heritable component with a heritability 
estimated to be 22% (1). Genome-wide association studies (GWAS) have identified 
approximately 35 loci associated with EOC risk (2-12). Most reported associations are specific to 
the most common histologic subtype, serous EOC (2-7,9-12). Together, known GWAS-
identified variants account for approximately 6.4% of EOC risk in the general population (12), 
indicating that additional susceptibility variants remain to be identified. In addition, genes that 
underlie the large majority of GWAS-identified risk loci remain unknown; most GWAS-
identified variants are located in noncoding genomic regions that may be involved in regulation 
of gene expression. Recent mechanistic studies have demonstrated that GWAS-identified 
variants are more frequently located in active chromatin regions, and highly-enriched with 
expression quantitative trait loci (eQTL)(13,14). This evidence underscores the importance of 
transcriptional regulation in influencing human traits and disease susceptibility.  
   
Prior studies on genetically-regulated gene expression were largely limited to easily accessible 
sources, such as adipose tissue and peripheral blood cells (15). Although the sample size in 
eQTL studies of peripheral blood cells recently reached the thousands, a relatively small number 
of genes are expressed in blood cells compared with other tissue types (14). Conclusions from 
eQTL studies in tumor tissue (e.g., TCGA) should also be interpreted with caution due to the 
inherent complexity of transcriptional regulation caused by acquired somatic alterations (16). 
The Genotype-Tissue Expression (GTEx) project provides high-density genotype data and RNA 
sequencing (RNA-seq) transcriptome data from 53 tissues (14). We used these data to build 
models of genetically regulated expression for 17,121 genes. We investigated the association 
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between these genetically-predicted gene expressions and EOC risk using data from 97,898 
women including 29,396 EOC cases. We identified 35 genes at 14 loci associated with EOC risk, 
and provide additional evidence of a potential role for dysregulated ovarian function and 
imbalanced ovarian hormone production in ovarian carcinogenesis.  
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Materials and Methods  
Genomic and transcriptomic data  
The GTEx preliminary cleaned genome-wide genotype data and RNA-seq transcriptome data 
across 53 unique tissues (released on 2015-01-12) were downloaded from dbGaP (accession 
phs000424.GTEx.v6.p1). It included 183 GTEx donors genotyped on Illumina’s Omni 5M and 
267 GTEx donors genotyped on Omni 2.5M. Genomic and transcriptomic data were processed 
according to the GTEx protocol (http://www.gtexportal.org/home/documentationPage). The 
Omni 2.5M portion of hard-called genotypes from the Omni 2.5M or Omni 5M across all 450 
donors were extracted and merged for analysis. We excluded variants with a genotyping call rate 
< 98%, with differential missingness between Omni 2.5M and Omni 5M arrays, with Hardy-
Weinberg equilibrium P-value<10-6 (for subjects of European ancestry), or with batch effects. 
Genotype data were imputed to the Haplotype Reference Consortium reference panel using 
minimac3 for imputation and SHAPEIT for prephasing (17). Variants with high imputation 
quality (R2 ≥ 0.8), minor allele frequency (MAF) ≥ 0.05, and inclusion in the HapMap Phase 2 
project were used to build predicted expression models.  
 
We used gene level expression in Reads Per Kilobase of transcript per Million mapped reads 
(RPKM) from RNA-SeQC for gene expression data. For ovarian transcriptomic data, genes were 
required to have expression in ≥10 individuals with >0.1 RPKM and raw counts >6. For our 
analysis of cross-tissue derived transcriptomic data (below), genes were filtered on mean 
expression levels with >0.1 RPKM and RPKM >0 required in at least 3 individuals (18). We 
performed quantile normalization to transform the expression profile of each sample to the same 
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scale, and performed inverse quantile normalization for each gene to map each set of expression 
values to a normal distribution. Residual expression was calculated by regressing transformed 
expression data against three top principal components (PCs) derived from common genetic 
variants (MAF ≥0.05), top 15 or 35 probabilistic estimation of expression residuals (PEER) 
factors respectively for ovarian tissue and cross-tissue derived models (below)(19), sex (for 
cross-tissue only) to correct for batch effects and other potential experimental confounders.  
 
European ancestry analysis of GTEx subjects 
The ancestral analysis was conducted with 2,836 ancestry informative markers for 450 GTEx 
individuals and 1,092 individuals included in the 1000 Genome project (Phase 1)(20). Of the 
individuals with both genotype and transcriptome data available, 369 were clustered together 
with EUR populations (CEU, FIN, GBR, IBS and TSI) on the multidimensional scaling plot of 
the pairwise Identity-By-State distance and were included in the analysis, 68 of whom had 
transcriptome data available for ovarian tissue. 
 
Orthogonal tissue decomposition derived cross tissue estimation  
Mixed effect models were used to decompose gene expression levels into subject-specific and 
subject-by-tissue-specific components (18). GTEx data consisted of expression measurements 
from multiple tissues for each subject. The expression level of a gene at a given tissue for 
individual i was considered to be composed of a cross-tissue component represented as YiCT and 
a tissue-specific component that was estimated as the difference between the expression levels 
and cross-tissue components given the lack of replicated measurement for a specific 
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tissue/subject pair (18). Zʹi represents a vector of covariates that have effects of β on the 
expression levels of the gene, such as PEER factors, ancestry information derived from the 
principal component analysis, and sex. The expression of a gene for individual i in tissue t, Yi,t, is 
modeled as  
Yi,t = YiCT + Zʹi β + ϵi,t 
The mixed effect model parameters were estimated using the lme4 package in R. Posterior 
modes of the subject level random intercepts were used as estimates of the cross-tissue 
components (18). Cross-tissue model included gene expression from 6,124 GTEx tissue samples 
from 369 unique European individuals who had genome-wide genotype data available. 
 
Ovarian-specific and cross-tissue genetically regulated expression model building 
We built an expression prediction model for each gene using the elastic net method as 
implemented in the glmnet R package, with a ridge-lasso mixing parameter of α = 0.5 and a 
penalty parameter lambda chosen through 10-fold cross-validation (18,21,22). The elastic net 
method with α = 0.5 is a compromise between the ridge-regression penalty (α = 0) for solutions 
with many parameters (each of small effects) and the lasso penalty (α = 1) for solutions with 
fewer parameters (each of large effects)(18). The genetically regulated expression for each gene 
was estimated by including SNPs within 1 Mb of the gene start or end, as defined by GENCODE 
V19 gene annotations. Expression prediction models were built for protein-coding genes, long 
non-coding RNAs (lncRNAs), microRNAs (miRNAs), processed transcripts, immunoglobulin 
genes, and T cell receptor genes, according to categories described in the GENCODE V19 gene 
annotation file. Pseudogenes were not included in the present study because of potential concerns 
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of inaccurate calling (23). Prediction r2 values (the square of the correlation between predicted 
and observed expression) were generated to estimate the prediction performance for each gene in 
our prediction models.  
 
With genome-wide genomic data and RNAseq-based tissue transcriptome data, we built an 
ovarian tissue cis genetically-regulated expression model for 8,580 genes that had predicted 
performance of r 2 > 0.01 and a cross-tissue cis genetically-regulated expression model for 
14,085 genes that had predicted performance of r2 > 0.01.  
 
Association analysis of predicted gene expression with EOC risk 
Associations between predicted gene expression levels and EOC risk were evaluated using 
MetaXcan (22). Briefly, the formula:  
௚ܼ ≈  ෍ ݓ௟௚
௟∈୑୭ୢୣ୪೒
ߪො௟
ߪො௚  
ߚመ௟
se(ߚመ௟)
  
was used to estimate the Z-score of the association between predicted gene expression and 
ovarian cancer risk. Here ݓ௟௚ is the weight of SNP ݈ for predicting the expression of gene ݃, 
ߚመ௟and se(ߚመ௟) are the association regression coefficient and its standard error for SNP ݈ in GWAS, 
and ߪො௟ and ߪො௚ are the estimated variances of SNP ݈ and the predicted expression of gene ݃ 
respectively. The input variables for the MetaXcan analyses include the weights for gene 
expression predicting SNPs, GWAS summary statistics results, and correlations between 
predictor SNPs. We integrated prediction models of gene expression levels with summary 
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statistics from GWAS of EOC risk for 97,898 European women with 29,396 EOC cases from the 
Ovarian Cancer Association Consortium (OCAC) and Consortium of Investigators of Modifiers 
of BRCA1/2 (CIMBA)(12) based on the variance and covariance matrix of genetic variants 
derived from 1000 Genome phase 3 EUR population (N = 503). The performance of MetaXcan 
has been shown to be similar to PrediXcan that uses individual level genetic data for the 
identification of genes with expression that is associated with disease risk (21,22).  
 
Details of individual contributing studies were previously reported (12). Briefly, the OCAC 
summary statistics were based on analysis of 40,941 controls and 25,509 population-based EOC 
cases (22,406 invasive cases and 3,103 borderline cases). OCAC cases included 1,954 serous 
borderline ovarian cancers, 1,149 mucinous borderline ovarian cancers, 1,417 mucinous invasive 
ovarian cancer, 1,012 low-grade serous ovarian cancers, 13,037 high-grade serous ovarian 
cancers, 2,810 endometrioid ovarian cancers, 1,366 clear-cell ovarian cancer and 2,764 other 
EOC cases. The CIMBA summary statistics were based on the analysis of 19,036 BRCA1 and 
12,412 BRCA2 mutation carriers, of whom 2,933 and 954, respectively, were diagnosed with 
EOC. Details of the genotyping procedure and QC have been described elsewhere (12). In brief, 
samples were excluded if they had a genotyping call rate < 95%, excessively low or high 
heterozygosity, if they were not female or had ambiguous sex, or were duplicates (cryptic or 
intended)(12). SNPs were excluded for a call rate <95%, deviating from Hardy-Weinberg 
equilibrium (P<10-7 in controls or unrelated samples in CIMBA and P <10-12 in cases) and 
concordance <98% among 5,280 duplicate pairs (12). All participants provided written informed 
consent and each contributing study was approved by the appropriate local institutional ethical 
review board. The studies were conducted in accordance with Declaration of Helsinki.  
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We used a Bonferroni-corrected P-value threshold of 2.21×10-6 (adjusting for 22,665 gene-tissue 
pairs) to determine a statistically significant association in our analysis. This threshold was 
conservative as 5,544 genes appeared in both ovarian and cross-tissue models. We did the 
primary analysis for high-grade serous EOC, as this had the largest sample size. In our secondary 
analyses, we also evaluated other histotypes or the combined histotypes, even though power to 
discover novel gene associations was relatively low for some (i.e. clear-cell, endometrioid, or 
low-grade serous). To determine whether associations identified between genetically-predicted 
gene expression and EOC risk were influenced by variants previously-identified by GWAS, we 
conducted conditional analyses adjusting for index SNPs. Briefly, we performed conditional 
analyses developed by Yang et al. (24) (GCTA-COJO) to calculate association betas and 
standard errors of SNPs with ovarian cancer risk after adjusting for index SNPs of interest. This 
was followed by re-performing MetaXcan analyses using updated summary statistics.  
 
Results 
Gene expression prediction model building 
We constructed genetically-regulated expression models based on genome-wide genotype data 
and RNA-seq transcriptome data from the GTEx project (14) (Supplementary Figure 1). Ovarian 
transcriptome data were available for 68 European individuals, and 8,580 genes achieved a 
prediction performance of r2 ≥0.01 in the ovarian model (Table S1). Because a large portion of 
cis expression regulation is shared across multiple tissues (14,18), we also used transcriptome 
data for 6,124 tissue samples from 369 European individuals to build cross-tissue models for 
14,085 genes with a prediction performance of r2 ≥0.01 (Table S1).  
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Association analyses between predicted gene expression and EOC risk 
We evaluated associations between predicted gene expression levels and EOC risk using 
MetaXcan (22) with summary statistics for individual GWAS SNPs from 97,898 European 
women including 29,396 EOC cases from OCAC and CIMBA(12) (Supplementary Figure 1). 
Our primary analysis focused on high-grade serous EOC; secondary analyses included other 
EOC histotypes (Supplementary Figure 1). 
 
In total, we identified 35 genes with genetically-predicted expression that were associated with 
EOC risk at a Bonferroni-corrected threshold of P <2.21×10-6 (Figure 1, Supplementary 
Figure 2, Supplementary Figure 3, Tables 1, 2 and S2). One gene at 11q14.2 (FZD4), was 
more than 1 Mb away from any GWAS-identified EOC susceptibility variant (Figure 1), 
suggesting a potential novel risk locus for this disease. High predicted FZD4 expression was 
associated with increased risk of high-grade serous EOC (Z = 5.08, P = 3.83 × 10-7, Figure 1). 
The remaining 34 genes were located within 1 Mb of previously identified EOC susceptibility 
variants (Tables 1, 2, S2 and S3), including 11 genes (at 8 loci) that were previously implicated 
in EOC risk using functional annotation, bioinformatic prediction, in vitro cellular models or 
known gene biology. Our study provides additional evidence to support these previous findings 
(Tables 2 and S3). However, 23 genes (at 6 known risk loci) had not been reported to be 
associated with EOC risk in prior studies (Tables 1 and S3). For 31 of these 34 genes, the 
associations were no longer statistically significant at P < 1.47 x 10-3 (multiple comparisons 
correction of 0.05/34) after adjustment for the nearest SNP identified by EOC GWAS (Table 
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S4), indicating that the previously identified GWAS SNPs for EOC at these 31 regions might 
regulate the expression of these associated gene to affect EOC risk. Associations for three genes 
(Z= 6.84 vs 3.27 for DNALI1, Z= 5.16 vs 3.81 for HOXD3 and Z= -8.60 vs -4.18 for CCDC171; 
Table 1, 2 and S4) remained statistically significant at P < 1.47 x 10-3 after adjusting for the 
nearest EOC risk SNP, although the strength of the association was attenuated. Four loci (2q31.1, 
9p22.3, 17q21.31 and 17q21.32) had multiple nearby genes associated with EOC risk (Tables 1 
and 2). This may be partially due to co-regulated gene expression in these chromosomal regions 
(Table S5 and Online Supplementary Material).  
 
Consistent with the etiologic heterogeneity of EOC(25), GWAS-identified risk variants differed 
across histologic subtypes(12). Therefore, we investigated associations between genes with P < 
2.21 × 10-6 across all major histotypes of EOC (Table S6). The majority of identified genes were 
associated with high-grade serous EOC risk, likely due to the large number of cases in our 
primary analysis. A few additional histotype specific associations were identified from secondary 
analyses. HOXD3 at 2q31.1 was associated with borderline mucinous EOC risk (Tables 2 and 
S6: Z = 5.16, P = 2.42 × 10-7). RP11-403A21.1 at 18q11.2 was associated with low-grade or 
borderline serous EOC risk (Tables 1 and S6: Z = -5.53, P = 3.13 × 10-8). ZNF546 at 19q13.2 
was associated with mucinous EOC risk (Tables 1 and S6: Z = 7.14, P = 9.07 × 10-13 for 
invasive/borderline mucinous EOC combined; Z = 5.99 and P = 2.14 × 10-9 for borderline 
mucinous EOC only). HOXD1 at 2q31.1 was associated with both invasive serous (Table S6: Z 
= 4.92, P = 8.55 × 10-7) and borderline mucinous (Table S6: Z = 5.24, P = 1.59 × 10-7) EOC 
risk. 
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Evidence from previous eQTL analyses of identified EOC susceptibility risk variants supports 
several currently identified gene associations (Tables 2 and S3). Reduced OBFC1 expression 
was associated with risk allele of GWAS identified EOC SNP at 10q24.33 (12), and we found 
that higher predicted OBFC1 expression was associated with lower EOC risk. Similarly, reduced 
RCCD1 expression was associated with risk allele of GWAS identified EOC SNP (11), and we 
found that higher predicted RCCD1 expression was associated with reduced EOC risk at 
15q26.1. In addition, multiple lines of evidence support our finding between higher predicted 
ABHD8 and increased EOC risk at 19p13.11. Increased ABHD8 expression was associated with 
risk allele of GWAS identified EOC SNP (26). Copy number variant analysis indicated that 
forty-six percent of high-grade serous EOC had amplification at 19p13.11 that contains ABHD8 
(3). 
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Discussion 
In this large transcriptome-wide association study (TWAS) among 97,898 women of European 
ancestry, we identified 35 genes with genetically-predicted expression levels associated with 
EOC risk. One of these genes (FZD4) is located more than 1 Mb away from any previously 
identified GWAS EOC variant (25 Mb away from the nearest reported EOC risk variant(11)), 
suggesting it is a potential novel risk locus. All other 34 genes identified were located within 1 
Mb of known GWAS loci, including 23 genes at 6 loci that had not previously been associated 
with EOC risk.  After adjustment for nearby known EOC GWAS-identified variants, the 
associations for 3 of the 34 genes retained. 
 
FZD4 is a member of the frizzled gene family that encodes seven-transmembrane domain 
proteins (Fzs) as the receptors for the secreted Wnts signaling ligands. Several Wnts and Fzs 
(including Fzd4 and Wnt4), as well as downstream targets of the canonical WNT signaling 
pathway, are expressed at different stages of ovarian follicular development, ovulation, and 
luteinization, suggesting specific functions for these signaling molecules in the mature 
ovary(27). Recent studies using transgenic mouse models demonstrated that Wnt4, Fzd4 and 
Ctnnb1 are required for normal folliculogenesis, luteogenesis and steroidogenesis, and that 
dysregulated WNT signaling leads to granulosa cell tumor development (27,28). FZD4-null 
female mice are infertile and exhibit reduced progesterone production, reduced luteinization-
associated gene expression, impaired corpora lutea formation and function, and impaired 
vascular development (28). Interestingly, WNT4 (1p36.12) encodes a potential Fzd4 binding 
ligand, which was also recently identified as a potentially causal gene underlying EOC risk by 
GWAS (Table S3)(7). Aberrant activation of WNT signaling in adult tissues has been implicated 
Research. 
on February 4, 2019. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 27, 2018; DOI: 10.1158/0008-5472.CAN-18-0951 
20 
 
in the pathogenesis of several types of cancer, including colorectal cancer (29). The positive 
association between FZD4 expression and invasive serous EOC risk suggests that dysregulated 
corpus luteum function and/or progesterone production may contribute to EOC pathogenesis.  
 
A locus 17q21.31 was previously identified by GWAS as associated with EOC risk (10,30). This 
region contains a 900-kb inversion in Europeans that has extensive linkage-disequilibrium likely 
due to restriction from crossovers in individuals who are heterozygous with respect to inversion 
(31). The H2 haplotype is less frequent (20% in Europeans) and is associated with higher number 
of children born to women (31). Interestingly, minor alleles of genetic variants in this region 
were almost universally associated with reduced breast cancer risk but increased EOC risk at 
genome-wide significance levels (Table S7 and Online Supplementary Material)(10,30). 
Permuth-Wey et al.(10) investigated several of these genes, including KIF18B, C1QL1, DCAKD, 
NMT1, PLCD3, ACBD4, HEXIM1, HEXIM2, FMNL1, C17orf46, MAP3K14, ARHGAP27, 
PLEKHM1, CRHR1, IMP5 and MAPT; extensive functional analysis suggested that ARHGAP27 
and PLEKHM1 may be EOC susceptibility genes (10). One of the other candidate genes at this 
region, CRHR1, is involved in regulating ovarian function; it is expressed in ovarian thecal cells, 
granulosa cells and luteal cells (32), and upregulated in EOC (10). High CRHR1 expression was 
almost universally associated with minor alleles of multiple genetic variants in this chromosome 
17 region (Table S8 and Online Supplementary Material)(33). Enhanced CRHR1 activation in 
the ovary leads to reduced production of testosterone(32) and estrogen(32,34-36), but increased 
progesterone accumulation and production (32). This may explain the lower breast cancer risk 
associated with variants in this region from lower estrogen exposure and higher progesterone 
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exposure associated with multiparity (31,37). Similarly, this also suggests that imbalanced 
estrogen and/or progesterone production contributes to EOC pathogenesis.  
 
Two of the candidate genes at the 17q21.32 locus, HOXB2 and HOXB3, belong to the homeobox 
gene family, which is important for normal vertebrate limb and organ development. This gene 
family was also recently shown to be enriched for genes underlying serous EOC risk by GWAS 
(38). Inconsistent tumorigenic effects of HOXB2 and HOXB3 were reported across several types 
of cancers (breast, pancreatic, lung, cervical cancer and acute myeloid leukemia)(39-43). This 
may be due to context-dependent effects from specific tumor microenvironments (39,43). With 
regard to ovarian cancer, increased HOXB2 and HOXB3 expression were associated with 
reduced EOC risk; potential molecular mechanisms underlying HOXB suppressive effect on 
EOC warrant further investigation.  
 
Several additional findings from this study are noteworthy. The precise function of DNALI1 at 
1p34.3 is not known. It is a potential candidate gene for primary cilia syndrome or Kartagener 
syndrome, in which the action of cilia lining the respiratory tract and Fallopian tube is 
compromised (44). A marked reduction in fertility was observed in female Kartagener's 
syndrome patients due to dysfunction of the oviductal cilia (45). The predicted expression of 
CCDC171 at 9p22.3 was associated with reduced EOC risk. CCDC171 was shown to interact 
with KRAS by a stringent screening for Ras-synthetic-lethal genes (46). Several lncRNAs were 
associated with EOC risk, including RP11-403A21.1 at 18q11.2 (Table 1). Little is known about  
their particular function in either tumor initiation or tumor development, but lncRNAs have been 
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increasingly implicated in many classic cancer biology pathways (47). In addition to HOXD3 and 
HOXD1 at 2q31.1 (Table 2 and Table S3)(4,8), ZNF546 at 19q13.2 was identified as a novel 
candidate gene for mucinous EOC. Enrichment for expression in gonadal tissues (14) supports a 
potential role in EOC pathogenesis. Because of the complexity of mucinous EOC, and 
undetermined cell/tissue of origin, identification of associated genetic variants and/or genes is 
particularly important (8,25). 
 
The tissue samples used in building gene expression models in GTEx (V6) came most from the 
people who recently died of traumatic injury (for these young donors) or cardio-cerebrovascular 
diseases (for the old donors). There were no overlaps between the tissues used in building gene 
expression models and the samples used in EOC GWAS in OCAC or CIMBA. Our ability to 
detect genes significantly associated with EOC risk is affected by tissue specificity and the 
sample size of the data set used to build genetic prediction models for gene expression. Four 
genes were identified from both ovarian and cross-tissue models; eight genes were only 
identified based on ovarian models; and twenty-three genes were only identified from cross-
tissue models (Table S2). The ovarian tissue transcriptome that we used to model gene 
expression was potentially derived from multiple ovarian cell types, including surface epithelial 
cells, oocytes, granulosa cells, Theca cells, luteal cells and other interstitial cells. Because of the 
importance of tissue or cell specific regulators (i.e., transcription factors or epigenomic features) 
in governing development and function, the ovarian-specific model should best capture 
transcriptional regulatory mechanisms of the ovary. However, in light of abundant shared cis 
regulation of expression across multiple tissues (14,18), we also pooled constitutive variant-
dependent regulatory information across tissues and built cross-tissue gene expression models. 
Research. 
on February 4, 2019. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 27, 2018; DOI: 10.1158/0008-5472.CAN-18-0951 
23 
 
We would expect this model to yield greater power as the number of tissues in which a variant is 
functional increases. By coupling both tissue specific and cross-tissue models, we aimed to 
robustly capture genetically regulated genes expression using a large sample size. Due to 
insufficient samples in the GTEx project, we did not build Fallopian tube-specific models.     
 
In summary, we identified one novel locus (FZD4) and 34 genes at 13 known EOC risk loci 
associated with EOC risk, and these findings may help improve our mechanistic understanding 
of EOC pathogenesis. In line with tentative observations of increased borderline EOC risk from 
ovarian hormone dysregulation for women who received fertility drug treatment with in vitro 
fertilization(48-50), the known biology of FZD4 and CRHR1 in the ovary implicates the 
potential of long-term dysregulated ovarian function or imbalanced ovarian hormone production 
as a possible mechanism underlying EOC pathogenesis. 
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Table 1. Association results for genes in known loci not previously reported in association with epithelial ovarian cancer risk 
Region Genea Z-score P value r2b Histotype Model GWAS Index SNPe Distance to the index SNP (kb) f 
1p34.3 DNALI1 6.84 7.84E-12 0.29 High-grade serousc cross-tissue rs58722170 64 
9p22.3 CCDC171 -8.60 8.08E-18 0.02 High-grade serousc ovary rs10962692 854 
9p22.3 C9orf92 -5.16 2.45E-07 0.15 High-grade serousc ovary rs10962692 640 
17q21.31 ADAM11 -4.86 1.19E-06 0.05 High-grade serousc ovary rs1879586 708 
17q21.31 AC091132.1 -7.18 7.02E-13 0.03 High-grade serousc cross-tissue rs1879586 26 
17q21.31 RP11-798G7.8 6.58 4.77E-11 0.05 High-grade serousc ovary rs1879586 42 
17q21.31 CRHR1 8.61 7.23E-18 0.60 High-grade serousc cross-tissue rs1879586 132 
17q21.31 RP11-105N13.4 6.77 1.33E-11 0.05 High-grade serousc ovary rs1879586 132 
17q21.31 MAPT-AS1 7.74 9.60E-15 0.10 High-grade serousc cross-tissue rs1879586 354 
17q21.31 RP11-669E14.6 -8.35 6.64E-17 0.30 High-grade serousc cross-tissue rs1879586 545 
17q21.31 KANSL1-AS1 8.26 1.48E-16 0.85 High-grade serousc cross-tissue rs1879586 704 
17q21.31 LRRC37A 8.38 5.08E-17 0.54 High-grade serousc ovary rs1879586 803 
17q21.31 LRRC37A2 8.26 1.44E-16 0.55 High-grade serousc ovary rs1879586 1022 
17q21.31 NSF -5.55 2.78E-08 0.02 High-grade serousc ovary rs1879586 1101 
17q21.32 RP11-138C9.1 5.54 3.04E-08 0.02 High-grade serousc cross-tissue rs7207826 741 
17q21.32 RP11-6N17.6 5.93 3.00E-09 0.19 High-grade serousc cross-tissue rs7207826 475 
17q21.32 PNPO 5.34 9.38E-08 0.30 High-grade serousc cross-tissue rs7207826 475 
17q21.32 PRR15L -4.91 9.18E-07 0.04 High-grade serousc cross-tissue rs7207826 465 
17q21.32 HOXB2 -5.48 4.28E-08 0.40 High-grade serousc cross-tissue rs7207826 118 
17q21.32 HOXB-AS1 -5.15 2.59E-07 0.29 High-grade serousc cross-tissue rs7207826 120 
17q21.32 HOXB3 -5.59 2.30E-08 0.12 High-grade serousc cross-tissue rs7207826 126 
18q11.2 RP11-403A21.1 -5.53 3.13E-08 0.11 Low grade/borderline serousd cross-tissue rs8098244 132 
19q13.2 ZNF546 7.14 9.07E-13 0.01 Invasive/borderline mucinousd ovary rs688187 757 
a ARHGAP27 and PLEKHM1 were previously considered as potential EOC candidate susceptibility genes by Permuth-Wey et al.(10) with an 
integrated molecular analysis of multiple genes at 17q21.31 locus (See Table 2 and Table S3);  
b r2 of tissue model's correlation to gene's measured transcriptome (prediction performance); 
c the analyses were based on summary statistics for high-grade serous ovarian cancers from Ovarian Cancer Association Consortium (OCAC) and 
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA);  
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d the analyses were based on summary statistics from OCAC; 
e See Table S4 for detailed information in selecting the GWAS index SNPs; 
f If the GWAS index SNP is located upstream of the gene, the gene start position is used; otherwise, the gene end position was used; LRRC37A2 
and NSF are within 1M of reported GWAS SNPs considering the association of all variants with EOC risk at P < 5×10-8 at this locus (See text and 
Table S4 for details). 
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Table 2. Association results for genes in known loci previously reported in association with ovarian cancer risk 
Region Gene Z-score P value r2a Histotype Model GWAS Index SNPe 
Distance to 
the index SNP 
(kb) f 
2q31.1 HOXD3 5.16 2.42E-07 0.04 Borderline mucinousc cross-tissue rs711830 0 
2q31.1 HOXD1 6.07 1.31E-09 0.04 High-grade serousb cross-tissue rs711830 16 
3q25.31 LEKR1 -5.81 6.24E-09 0.46 High-grade serousb cross-tissue rs62274041 108 
8q21.13 CHMP4C -6.69 2.24E-11 0.47 High-grade serousc cross-tissue rs11782652 0 
9q34.2 ABO 5.44 5.37E-08 0.49 High-grade serousb ovary rs635634 4 
10q24.33 OBFC1 -5.09 3.66E-07 0.01 Borderline serousc cross-tissue rs7902587 16 
15q26.1 RCCD1 -5.46 4.64E-08 0.59 High-grade serousc  cross-tissue rs8037137 0 
17q21.31d PLEKHM1 4.80 1.59E-06 0.01 High-grade serousb cross-tissue rs1879586 0 
17q21.31d KANSL1 4.74 2.15E-06 0.18 High-grade serousb ovary rs1879586 540 
17q21.31d WNT3 6.81 9.82E-12 0.40 High-grade serousb cross-tissue rs1879586 1273 
19p13.11 ABHD8 4.79 1.69E-06 0.23 High-grade serousb cross-tissue rs4808075 13 
a r2 of tissue model's correlation to gene's measured transcriptome (prediction performance); 
b the analyses were based on summary statistics for high-grade serous ovarian cancers from Ovarian Cancer Association Consortium (OCAC) and 
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA);  
c the analyses were based on summary statistics from OCAC; 
d Eleven novel genes associated with EOC risk at this locus were presented in Table 1; 
e See Table S4 for detailed information in selecting the GWAS index SNPs; 
f If the GWAS index SNP is located upstream of the gene, the gene start position is used; otherwise, the gene end position was used; WNT3 is 
within 1M of reported GWAS SNPs considering the association of all variants with EOC risk at P < 5×10-8 at this locus (See text and Table S4 for 
details). 
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Figure 1 | Regional plot of OCAC and CIMBA GWAS summary statistics around the FZD4 gene associated with high-grade serous 
EOC risk (Z = 5.08, P = 3.83 × 10-7 based on the cross-tissue model of r2 = 0.07, see supplementary Table 2 for details). Each symbol 
represents the significance (P value on a log10 scale) of a SNP with invasive EOC risk as a function of the SNP’s genomic position 
(NCBI Build 37). The most significantly associated SNP is represented in the purple color. The color of all other SNPs indicates LD 
with this SNP (estimated by EUR r2 from the 1000 Genome Project data). Recombination rates were also estimated from 1000 
Genome Project data, and gene annotations were obtained from the UCSC Genome Browser. The circle shape denotes the SNPs 
included in the model construction of genetically regulated FZD4 expression and the square shape denotes the SNPs not included in 
the model construction. The gene model was constructed including SNPs within 1 Mb of the gene start or end, and one SNP included 
in the model construction was located outside the 1Mb window size of the locus zoom plot (rs7944482 at chr11:86091532, P = 0.52 
for association with high-grade serous EOC risk).  
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